SCHEMBL17633302

SCHEMBL17633302

COc1cc(-c2cc(Cl)ccc2C#N)c(C)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
SCN9A Q15858 3/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SRC P12931 6/20 0.39
F11 P03951 2/20 0.38
PRKCQ Q04759 1/20 0.37
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
SLC22A12 Q96S37 2/20 0.36
EGFR P00533 2/20 0.36
ERBB2 P04626 2/20 0.36
S1PR3 Q99500 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16114779 0.90 SRC (0.43) KDM4EMAPTTDP1SRCPRKCQ
SCHEMBL16115569 0.88 KDM4E (0.42) KDM4EMAPTTDP1SRCF11
SCHEMBL30343103 0.86 SRC (0.44) SRCF11PRKCQABL1BCR
SCHEMBL16115246 0.86 SRC (0.44) SRCF11PRKCQABL1BCR
SCHEMBL17633224 0.85 SRC (0.42) KDM4EMAPTTDP1SRCF11
SCHEMBL16114685 0.85 SRC (0.42) SCN9AKDM4EMAPTTDP1SRC
SCHEMBL16114739 0.83 F11 (0.41) KDM4EMAPTTDP1SRCF11
SCHEMBL16116102 0.82 AR (0.43) F11EGFRERBB2MEN1KMT2A
SCHEMBL16114865 0.82 KDM4E (0.46) KDM4EMAPTTDP1SRCF11
SCHEMBL17633279 0.81 ABL1 (0.38) SCN9AKDM4EMAPTTDP1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197872-B1 (2H)-2-OXOPYRIDINES AS FAKTOR XIA-INHIBITORS FOR TREATING THROMBOTIC DISEASES Bayer Pharma AG (DE) 2019-01-30 EP disclosed
EP-3197872-B1 (2H)-2-OXOPYRIDINES AS FAKTOR XIA-INHIBITORS FOR TREATING THROMBOTIC DISEASES Bayer Pharma AG (DE) 2019-01-30 EP disclosed
US-10167280-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-01-01 US disclosed
US-20170291892-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-10-12 US disclosed
US-20170291892-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-10-12 US disclosed
US-20170291892-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-10-12 US disclosed
EP-3197872-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2017-08-02 EP disclosed
WO-2016046166-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-03-31 WO disclosed
WO-2016046166-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10167280-B2 Substituted oxopyridine derivatives OGFOD1, PNPO, VASP JAK2 324/4885JAK1 600/4885TYK2 1179/4885
US-20170291892-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, PNPO, VASP JAK2 324/4885JAK1 600/4885TYK2 1179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.